Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AgfiledCriticalSchering Ag
Publication of UY27690A1publicationCriticalpatent/UY27690A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
La invención se refiere al uso de ésteres de estriol, por ejemplo, a 3,17-dipropionato de estriol o a 3,17- dihexanoato de estriol, para el tratamiento de enfermedades autoinmunes, como por ejemplo esclerosis múltiples (MS).The invention relates to the use of estriol esters, for example, to 3.17-estriol dipropionate or 3.17-estriol dihexanoate, for the treatment of autoimmune diseases, such as multiple sclerosis (MS).
UY27690A2002-02-272003-02-27
USE OF ESTRIOL DIESTER BIOGEN DRUGS FOR THE TREATMENT OF DISEASES.
UY27690A1
(en)
COMPOUNDS DERIVED FROM OXIMAS; PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM; AND ITS USE AS USEFUL IMMUNOSUPPRESSORS IN DISEASES MEDIATED BY THE EDG RECEIVER, TALEES AS AUTOIMMUNE, INFLAMMATORY, INFECTIOUS AND CANCER DISEASES.
PHARMACEUTICAL COMPOSITIONS THAT INCLUDE A COMBINATION OF RAPAMYCIN OR ITS DERIVATIVE AND PIMECROLIMUS FOR THE TREATMENT OF INFLAMMATORY AND IMMUNOLOGICALLY MEDIATED DISEASES